- Bupa Platinum consultant
- Fee assured
- Verified account
- Open Referral network
- Home chemotherapy
Dr Gabriel qualified in medicine from St Mary’s Hospital Medical School - Imperial College in 1999 and completed his specialist training in haematology in London. He holds a joint consultant position with Imperial College NHS Healthcare Trust (Hammersmith Hospital) where he is a consultant in haemato-oncology (myeloma) and stem cell transplantation (autologous and allogeneic) and at Chelsea and Westminster where he leads the service for blood cancers including myeloma, lymphoma, myelodysplasia and leukaemia. He was awarded the Frank Cass Scholarship to pursue research and completed his PhD at Imperial College, researching the role of killer immunoglobulin receptors in post-transplant tumour eradication and and graft versus host reactions.
His main interest is in haemato-oncology (blood cancers) and stem cell transplantation. He is one of the leading stem cell transplant clinicians for stem cell treatment for multiple sclerosis, leading the service at Imperial College, one of the two largest centres in the UK.
A founder member of the European Consortium for Stem Cell Mobilisation (ECOSM), he is a member of the European Blood and Marrow Transplant Group (EBMT) autoimmune disease and acute leukaemia working parties. He is primary and co-investigator on a number of National and International clinical trials in haematology and also runs a general haematology clinic including anti-coagulation.
Dr Gabriel has published peer reviewed papers on lymphoma, myeloma, leukaemia, and HIV haematology in addition to those on stem cell transplantation. He is the author of a number of book chapters.
Areas of interest
Haematological Malignancy: Multiple Myeloma Lymphoma, Leukaemia, & Myelodysplasia
Stem Cell Transplantation (Allogeneic and Autologous)
Stem Cell Transplantation for Multiple Sclerosis
General haematology including coagulation disorders
Current NHS consultant posts held
Chelsea and Westminster Hospital. Consultant haematologist - lead clinician for haematological cancers.
Imperial College NHS Healthcare Trust (Hammersmith Hospital). Consultant haematologist - lead for transplantation for autoimmune disease - Multiple Sclerosis (One of the largest Centres in Europe for MS transplant.
His main interest is in haemato-oncology and stem cell (bone Marrow) transplantation.
Multiple sclerosis tranplant
Stem Transplantation (cancer and autoimmune disease)
Transplantation in HIV patients
Natural Killer cell biology.
Smith and Nephew Pharmaceuticals Scholarship for research.
The Frank Cass Scholarship for postgraduate research
HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. Nature 2019
Autologous Transplant in Multiple Sclerosis- The London Experience. ECTRIMS 2019.
Clinical proof of concept for a safe and effective NF-κB-targeting strategy in multiple myeloma 2109
Long-Term Outcome of Allogeneic Hematopoietic Cell Transplantation for Patients with Mycosis Fungoides and Sézary Syndrome: An EBMT Lymphoma Working Party Extended analysis. Journal of Clinical Oncology
KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with Imatinib. Leukaemia
Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology
Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma. Blood
Autologous stem-cell transplantation in patients with HIV-related lymphoma.Journal of Clinical Oncology
Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood
EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplant procedure. Biology of Blood and Marrow transplant
European Data on Stem Cell Mobilization with Plerixafor in Non-Hodgkin’s Lymphoma, Hodgkin’s Lymphoma and Multiple Myeloma Patients. Bone Marrow Transplant
Plerixafor for autologous peripheral blood stem cells mobilization in patients previously treated with fludarabine or lenalidomide. Biology of Blood and Marrow transplant
Tyrosine kinase inhibitors impair B-cell immune response in CML through off-target kinases important for cell signalling. Blood
Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia. Blood
Higher BMI is not a barrier to stem cell mobilization with standard doses of Plerixafor and G-CSF. Bone Marrow Transplant
Graft Versus Lymphoma Effect after Early Relapse following Reduced Intensity Sibling Allogeneic Stem Cell Transplantation for Relapsed Cytotoxic Variant of Mycosis Fungoides. Bone Marrow Transplant
- MB BS MRCP(UK) FRCPath BSc(Hons) PhD St Mary’s Hospital Medical School - Imperial College 1999
Reference number 4642514
Details of entry to specialist register
- Haematology Specialist Register , 2010
Affiliations / memberships
British Society of Haematology, Royal College of Pathologists, European Group for Blood and Marrow Transplantation, European Consortium for Stem Cell Mobilisation, British HIV Association.
- 102 Sydney Street (Lister)
- 17:30 - 20:00
- 020 7317 2562
- BUPA Cromwell 164-178 Cromwell RoadLONDONSW5 0TU
- 18:00 - 20:00
- 020 7460 5700
- Chelsea & Westminster Hospital, SW10 9NH
- 07:30 - 20:00
- 020 3315 8484
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
In the event of an urgent query following treatment, Bupa members should use the following contact details
Dr Ian Gabriel 02073172660
Information for healthcare professionals (Bupa patients only, last 12 months)
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-28 days - (>50)
Lister Hospital (>50)
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-21 days - (5-50)
Lister Hospital (5-50)
Intravenous infusion (as sole procedure) - (5-50)
Lister Hospital (5-50)
Therapeutic venesection - (5-50)
Lister Hospital (5-50)
Peripherally inserted central venous catheters (PICCs) under x-ray guidance - (1-5)
- Show All (7 )...